Related Experiment Video
Updated: Apr 20, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion
Oriol Yélamos1, Alba Català, Eva Vilarrasa
1Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background:
Methotrexate (MTX) is considered a relatively safe drug when prescribed at low-dose regimens not exceeding 25 mg/week. Severe acute toxicity is rare and presents with mucositis, cutaneous ulceration and pancytopenia. Most cases occur as the result of inadvertent overdosing due to erroneously taking the drug daily. However, concomitant factors such as older age, co-medication and renal failure may increase the drug's toxicity.
Case Reports:
We report four consecutive cases of acute MTX toxicity in patients with psoriasis vulgaris. In three patients, MTX was erroneously taken daily for 2-4 weeks. All three patients recovered following MTX withdrawal and intensive treatment. The fourth patient was taking 7.5 mg weekly MTX as prescribed, but had concomitant factors and died.
Conclusion:
Although low-dose MTX appears to be a safe medication, acute MTX toxicity can be a life-threatening emergency. Greater awareness of possible MTX toxicity is still needed for its prevention, early diagnosis and management.
Insights
Methotrexate (MTX) toxicity can be life-threatening, even at low doses. Accidental daily intake or underlying conditions increase risks, necessitating greater awareness for prevention and early management.
Area of Science:
- Dermatology
- Pharmacology
- Toxicology
Background:
- Methotrexate (MTX) is a widely used drug, generally safe at low doses (≤25 mg/week).
- Severe acute toxicity is rare but can manifest as mucositis, cutaneous ulceration, and pancytopenia.
- Risk factors include inadvertent daily dosing, older age, co-medication, and renal failure.
Observation:
- Four cases of acute MTX toxicity in psoriasis vulgaris patients were analyzed.
- Three patients experienced toxicity due to erroneously taking daily MTX for 2-4 weeks.
- One patient on prescribed weekly MTX (7.5 mg) died due to concomitant factors.
Findings:
- Acute MTX toxicity can occur even with standard low-dose regimens.
- Erroneous daily dosing significantly elevates the risk of severe adverse events.
- Concomitant factors like renal impairment exacerbate MTX toxicity.
Implications:
- Increased clinical awareness of MTX toxicity is crucial for prevention.
- Early diagnosis and prompt management are vital for improving patient outcomes.
- MTX toxicity, though rare, represents a potentially life-threatening emergency requiring careful patient monitoring.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug Toxicity: Dose-Dependent Reactions

